“Tirzepatide is just a stronger version of Ozempic.”
What the evidence shows
Tirzepatide does produce greater average weight loss than semaglutide: the head-to-head SURMOUNT-5 randomized trial (NEJM, 2025) found roughly 20% mean body-weight reduction with tirzepatide versus about 14% with semaglutide over 72 weeks in adults with obesity and no diabetes. So on the single axis of average weight lost, "stronger" is fair.
What we still don’t know
It is not settled how much of that extra effect comes from the added GIP receptor target versus simply a higher effective level of GLP-1 activity. We also lack long, decade-scale head-to-head data, and whether a given person does better on one drug than the other is not predictable from the trial averages.
Why the claim misleads
"Just a stronger version of Ozempic" frames tirzepatide as a dose upgrade of the same drug, but it is a different molecule that activates two receptors (GLP-1 and GIP), not one — pharmacology studies describe it as an imbalanced dual GIP/GLP-1 agonist. The side-effect and tolerability profile also differs, so "same drug, more of it" is the wrong mental model even though tirzepatide's average results are larger.
Source: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
Graded by The Peptide Era · evidence, not hype